Moreover, in translational trials for CRC therapy, antagonists of the CXCR4/CXCR7/CXCL12 axis need to be investigated in combination with chemotherapy, angiogenesis inhibitors, or immunotherapy. Here, ACKR3 is linked to colorectal carcinoma.